4.6 Review

Writing Histone Monoubiquitination in Human Malignancy-The Role of RING Finger E3 Ubiquitin Ligases

Journal

GENES
Volume 10, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/genes10010067

Keywords

E3 ligase; RING finger; monoubiquitination; histone; chromatin; RNF20; RNF40; polycomb repressor complex 1; RING1B; BRCA1

Ask authors/readers for more resources

There is growing evidence highlighting the importance of monoubiquitination as part of the histone code. Monoubiquitination, the covalent attachment of a single ubiquitin molecule at specific lysines of histone tails, has been associated with transcriptional elongation and the DNA damage response. Sites function as scaffolds or docking platforms for proteins involved in transcription or DNA repair; however, not all sites are equal, with some sites resulting in actively transcribed chromatin and others associated with gene silencing. All events are written by E3 ubiquitin ligases, predominantly of the RING (really interesting new gene) finger type. One of the most well-studied events is monoubiquitination of histone H2B at lysine 120 (H2Bub1), written predominantly by the RING finger complex RNF20-RNF40 and generally associated with active transcription. Monoubiquitination of histone H2A at lysine 119 (H2AK119ub1) is also well-studied, its E3 ubiquitin ligase constituting part of the Polycomb Repressor Complex 1 (PRC1), RING1B-BMI1, associated with transcriptional silencing. Both modifications are activated as part of the DNA damage response. Histone monoubiquitination is a key epigenomic event shaping the chromatin landscape of malignancy and influencing how cells respond to DNA damage. This review discusses a number of these sites and the E3 RING finger ubiquitin ligases that write them.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, Research & Experimental

Toward Systems Pathology for PTEN Diagnostics

Nahal Haddadi, Glena Travis, Najah T. Nassif, Ann M. Simpson, Deborah J. Marsh

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2020)

Article Biochemistry & Molecular Biology

Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways

Alexander J. Cole, Kristie-Ann Dickson, Christopher Liddle, Clare Stirzaker, Jaynish S. Shah, Roderick Clifton-Bligh, Deborah J. Marsh

Summary: The cancer-associated chromatin landscape is altered in response to therapeutic DNA damage, influencing gene expression and cell fate. Following treatment, there is a reduction in global levels of H2Bub1 and an increase in p53 levels. However, H2Bub1 is enriched downstream of specific genes, including key cancer-related genes, regulating gene expression and cellular response to therapeutic DNA damage.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

Article Biochemistry & Molecular Biology

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer

Kristie-Ann Dickson, Tao Xie, Christian Evenhuis, Yue Ma, Deborah J. Marsh

Summary: PARP inhibitors have shown efficacy in treating tumors with BRCA gene defects, improving survival outcomes. Variability exists between different PARP inhibitors in terms of chemical structure, toxicity, and cell survival, with acquired resistance being a concerning issue that needs further exploration.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Cell Biology

Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling

Christine Bolitho, Michelle Moscova, Robert C. Baxter, Deborah J. Marsh

Summary: AREG plays a significant role in EOC, promoting migration and proliferation of EOC cells through activation of PI3-K signaling, independent of MAPK signaling. Both autocrine loop of AREG and the activity of endogenous AREG impact EOC cell migration and proliferation.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2021)

Review Biotechnology & Applied Microbiology

Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine

Christine Yee, Kristie-Ann Dickson, Mohammed N. Muntasir, Yue Ma, Deborah J. Marsh

Summary: Ovarian cancer has the highest mortality rate among gynecological malignancies. Different histotypes of the cancer respond differently to treatments, with chemoresistance being a key factor in incurable disease. While PARP inhibitors and bevacizumab are currently used in clinical settings, further research is needed to predict patient responses to these drugs effectively.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)

Article Pharmacology & Pharmacy

The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells

Dongli Liu, Gunnar F. Kaufmann, James B. Breitmeyer, Kristie-Ann Dickson, Deborah J. Marsh, Caroline E. Ford

Summary: This study investigated the potential of Zilovertamab, a ROR1-targeting therapy, in treating high-grade serous ovarian cancer and endometrial cancer. The results showed that Zilovertamab alone could inhibit tumor cell proliferation, but its combination with commonly used chemotherapy drugs did not enhance the anti-proliferative activity.

PHARMACEUTICS (2022)

Review Oncology

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival

Tao Xie, Kristie-Ann Dickson, Christine Yee, Yue Ma, Caroline E. Ford, Nikola A. Bowden, Deborah J. Marsh

Summary: Synthetic lethality approaches involving the combination of events have shown significant advances in the treatment of women with ovarian cancer who have defects in the HRR pathway. PARP inhibitors have been approved for the clinical management of ovarian cancer, but challenges remain in overcoming acquired resistance, extending benefits to more patients, combining with other drugs, and developing new therapies.

CANCERS (2022)

Review Oncology

PTEN, PTENP1, microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics

Glena Travis, Eileen M. Mcgowan, Ann M. Simpson, Deborah J. Marsh, Najah T. Nassif

Summary: PTENP1, the processed pseudogene of PTEN, acts as a competitive endogenous RNA to alter the abundance of PTEN by competing with specific miRNAs for binding. Disruption of the PTENP1-miRNA-PTEN axis may lead to cancer but also provide novel therapeutic opportunities.

CANCERS (2023)

Article Materials Science, Biomaterials

An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles

Nidhi Joshi, Dongli Liu, Kristie-Ann Dickson, Deborah J. Marsh, Caroline E. Ford, Martina H. Stenzel

Summary: This study investigated the delivery of ROR2 siRNA into HGSOC cells using nanoparticles and found that ROR2 siRNA conjugated PICs nanoparticles significantly inhibited migration and invasion ability. This suggests that ROR2 targeting therapy using biocompatible nanoparticles shows promise in treating HGSOC, including platinum resistant forms.

JOURNAL OF MATERIALS CHEMISTRY B (2021)

No Data Available